Skip to main content
新芝生物 logo

新芝生物 — Investor Relations & Filings

Ticker · 920685 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2026-04-26 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920685

About 新芝生物

https://www.scientz.com/

Scientz Biotechnology specializes in the design and manufacture of high-performance life science instruments and laboratory equipment. The product range features ultrasonic cell disruptors, freeze dryers, gene guns, and high-pressure homogenizers, which are essential for sample preparation, cell lysis, and genetic engineering. The company also provides specialized solutions for tissue grinding, ultrasonic cleaning, and precise temperature control. These instruments serve a broad spectrum of applications in molecular biology, pharmaceutical research, environmental science, and agricultural technology. By integrating advanced ultrasonic and cryogenic technologies, Scientz supports research institutions and industrial laboratories in achieving accurate and reproducible results across various scientific disciplines.

Recent filings

Filing Released Lang Actions
立信会计师事务所（特殊普通合伙）关于宁波新芝生物科技股份有限公司2025年度募集资金存放、管理与使用情况专项报告的鉴证报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled '2025年度募集资金存放、管理与使用情况专项报告' which translates to '2025 Annual Report on the Custody, Management and Use of Raised Funds'. It includes an auditor's assurance report (鉴证报告) issued by a certified public accounting firm, referencing compliance with Chinese securities regulatory rules specifically related to the management of raised funds by listed companies. The document contains extensive financial data on the amount of funds raised, their usage, management, and cash management activities during the 2025 fiscal year. It also includes auditor's responsibilities, conclusions, and certifications. The document is over 13,000 characters, indicating it is a full report rather than a brief announcement. The content focuses on the management and use of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual report (10-K), audit report (AR) in the traditional sense of financial statement audit, or other categories. The document is a specialized report on the use and management of fundraising proceeds, which fits best under Capital/Financing Update (CAP).
2026-04-26 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "2025年年度报告" which translates to "2025 Annual Report" for 宁波新芝生物科技股份有限公司 (Ningbo Scientz Biotechnology Co., Ltd). It contains detailed sections typical of an annual report, including company overview, accounting data and financial indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, governance, and full financial accounting reports. The document includes audited financial data, management certifications, and comprehensive business and financial analysis for the fiscal year 2025 (January 1, 2025 to December 31, 2025). The length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. The presence of detailed financial statements, management discussion, and audit opinions confirms this is the full official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-26 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Ningbo Xinzhi Biotechnology Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It includes extensive tables listing various bank financial products, amounts, expected yields, terms, and other details related to the company's cash management activities using idle raised funds. The document is lengthy (15,000 characters) and focuses on the company's financing and capital management activities rather than financial results, management changes, or legal matters. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. The content is specifically about updates on the company's fundraising capital usage and cash management, which fits the definition of a Capital/Financing Update (CAP).
2026-04-07 Chinese
关于控股子公司减资暨完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Ningbo Xinzhi Biotechnology Co., Ltd. regarding a capital reduction and completion of industrial and commercial registration changes for its controlling subsidiary. It details the board resolution, capital increase and subsequent reduction, and the updated business license information. The document is short (1051 characters) and focuses on corporate actions related to capital structure changes of a subsidiary, not a full financial report or audit. It is not a report itself but an announcement of a corporate event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2026-03-29 Chinese
股东拟减持股份的预披露公告（再次披露）
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder's planned reduction of shares. It details the shareholder's identity, shareholding percentage, planned reduction quantity, methods, timing, and compliance with relevant laws and regulations. It also includes risk warnings related to the share reduction plan. The document is not a financial report, earnings release, or management discussion, but rather an official announcement about a shareholder's intention to reduce holdings. This fits the category of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2026-03-12 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Ningbo Xinzhi Biotechnology Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It includes specifics about authorized cash management, types of financial products invested in, amounts, expected yields, investment terms, and risk control measures. The document is a regulatory announcement about the company's use of idle raised funds for cash management, not a financial report or earnings release. It does not contain comprehensive financial statements or management discussion of results, nor is it a proxy, AGM material, or legal proceeding. The document is lengthy (15,000 characters) and provides detailed disclosure about cash management activities, consistent with a Capital/Financing Update (CAP) filing type, which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is CAP with high confidence.
2026-03-03 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.